Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceu (NQ: RARE )

47.24 +1.22 (+2.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceu

< Previous 1 2 3 4 5 6 7 8 Next >
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
AT&T, Union Pacific, Las Vegas Sands And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 30 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
Via Benzinga
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
Via Benzinga
Stocks Fall As Bond Yields Hit Multi-Year Highs
The major indexes are firmly lower this afternoon, with both the Dow Jones Industrial Average and Nasdaq Composite down triple digits as bond yields rise. 
Via Talk Markets
Topics Bonds Stocks
Exposures Debt Markets US Equities
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Ultragenyx Announces Proposed Public Offering of Common Stock
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Why Is Mereo BioPharma Stock Trading Higher Today?
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) released interim data from the Phase 2 portion of the Phase 2/3 Orbit  
Via Benzinga
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
Analyst Day will be webcast beginning at 8:30 a.m. ET on Monday, October 16 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate at Investor Conferences in September
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Initial data expected in first half of 2024 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
The company is one of the first in the U.S. with complete end-to-end gene therapy capabilities in Massachusetts, from research and development to therapeutic production at scale 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.